Abstract
The expression of the c-erbB-2 oncogene has been evaluated using an immunohistochemical technique with the 21N polyclonal antibody in paraffin embedded tissue from 465 patients treated between the years 1975-1981 for Stage I and II breast cancer. One hundred and four (22%) patients exhibited positive staining. This was not associated with any other variables. Expression of the oncogene was associated with significantly poorer survival which was independent of other tumour variables.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Winstanley, J., Cooke, T., Murray, G. et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63, 447–450 (1991). https://doi.org/10.1038/bjc.1991.103
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.103
- Springer Nature Limited
This article is cited by
-
A review of prognostic and predictive biomarkers in breast cancer
Clinical and Experimental Medicine (2022)
-
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer
Breast Cancer Research and Treatment (2020)
-
Prognostic Significance of Metabolic Parameters and Textural Features on 18F-FDG PET/CT in Invasive Ductal Carcinoma of Breast
Scientific Reports (2019)
-
Retrospective analysis of metastatic behaviour of breast cancer subtypes
Breast Cancer Research and Treatment (2015)
-
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
Breast Cancer Research and Treatment (2013)